BUSINESS

• Kowa’s Parmodia Most Heavily Pitched for GPs in June: Anterio
  August 31, 2018

• Global Biologic Market Rises 13.9% to 18.6 Trillion Yen in FY2017 Driven by I/O Drugs
  August 31, 2018

• With Bullish Maviret, AbbVie Aims for Double-Digit Growth to Join Top 20 in 2018
  August 30, 2018

• South Korea OKs Lenvima for 1st Line HCC: Eisai
  August 30, 2018

• Eisai/Biogen’s Alzheimer’s Drug Aducanumab Shows Continued Efficacy in Long-Term Extension PIb Study
  August 30, 2018

• Imfinzi, Gazyva Now Available in Japan
  August 30, 2018

• Celltrion Launches Herceptin Biosimilar in Japan
  August 29, 2018

• Ono Hooks Up with BMS, Clovis to Develop Opdivo/Rucaparib Combo Therapy in Japan, S. Korea, Taiwan
  August 29, 2018

• I/O in Lung Cancer - 3: Pfizer Sets Sights on Ovarian Cancer after NSCLC Trial Fails
  August 28, 2018

• Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
  August 28, 2018

• New AG Re-Pricing Rule Erodes 10 Billion Yen from Daiichi Sankyo Espha Sales
  August 28, 2018

• Gilead, JT Start Talks on Terminating Japan HIV Pacts
  August 27, 2018

• Opdivo Price Cut Won’t Have Much Impact on Financial Results: Ono
  August 27, 2018

• Pfizer, Astellas Move UP Completion Dates for 2 Xtandi Studies
  August 24, 2018

• Kyowa Kirin Mum on Listing Request Status for Nesp “Biosame”
  August 24, 2018

• Novo’s Ozempic Listing Plan Hobbled by 14-Day Prescription Rule?
  August 24, 2018

• Lenvima Approved for 1st Line HCC Use in Europe: Eisai/Merck
  August 24, 2018

• Shire Japan, Medipal Introduce Emergency Delivery System for Hemophilia Treatment
  August 23, 2018

• MSD Launches Antibacterial Agent Sivextro
  August 23, 2018

• Takeda, Ono Join Hands in Japan PIII for Opdivo-Cabozantinib Combo
  August 23, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 373
• 374
• 375
• 376
• 377
• 378
• 379
• 380
• 381
• …
• Next ›
• 最終 »